TLDR LULU reports Q4 FY25 earnings on Tuesday, March 17, after market close. Analysts expect EPS of $4.78, down 22.2% year-over-year, and revenue of $3.57 billionTLDR LULU reports Q4 FY25 earnings on Tuesday, March 17, after market close. Analysts expect EPS of $4.78, down 22.2% year-over-year, and revenue of $3.57 billion

Lululemon (LULU) Stock: Buy the Dip or Value Trap Before Tuesday’s Earnings?

2026/03/16 17:10
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • LULU reports Q4 FY25 earnings on Tuesday, March 17, after market close.
  • Analysts expect EPS of $4.78, down 22.2% year-over-year, and revenue of $3.57 billion, down 1.1%.
  • The stock is down ~24% year-to-date and over 50% in the past 12 months.
  • Wall Street holds a consensus Hold rating, with an average price target of $205.53 — about 30% above current levels.
  • CEO Calvin McDonald is stepping down, with a replacement search ongoing.

Lululemon heads into Tuesday’s earnings report with its stock sitting near a multi-year low. LULU is down about 24% this year and has shed more than half its value over the past 12 months. The pressure is on.


LULU Stock Card
Lululemon Athletica Inc., LULU

Analysts expect the company to post Q4 revenue of $3.57 billion, a 1.1% drop year-over-year. That’s a sharp reversal from the 12.7% growth it put up in the same quarter last year. EPS is forecast at $4.78, which would represent a 22.2% decline.

Earlier this year, management said Q4 results could come in near the high end of guidance, pointing to solid holiday demand, heavy store traffic, and strong seasonal promotions including Black Friday.

Peers in the apparel space have had a mixed earnings season. Tilly’s grew revenue 5.3% and beat estimates, jumping 46.4% post-results. Zumiez grew 4.4% but still fell 10.9% after its report. The sector overall is down about 9.7% over the last month.

LULU has missed Wall Street’s revenue estimates multiple times over the past two years. Analysts haven’t moved their estimates much in the last 30 days, suggesting they expect the company to hold steady rather than surprise.

Leadership in Flux

In January, CEO Calvin McDonald announced he would step down after leading the company since 2018. He’s expected to stay on as a senior advisor through March 31 while the search for a new CEO continues.

If a new chief executive is announced alongside the earnings, the market could react positively. A leadership change of that kind tends to reset investor expectations.

International Growth as a Bright Spot

North American store traffic has been slowing, and U.S. growth guidance has been cut. But Lululemon has been pushing hard into international markets — particularly China and Mexico — with new store openings designed to offset domestic softness.

That international strategy is one of the few clear growth levers available to the company right now.

On valuation, LULU currently trades at a forward P/E of about 12.1x, well below the sector average of around 16x. That gap suggests much of the recent bad news may already be priced in.

Macroeconomic headwinds remain a concern. Tariff uncertainty, inflation, and cautious consumer spending — especially among lower-income shoppers — could weigh on results. Competition in the athleisure market is also intensifying.

Wall Street’s consensus is a Hold, based on one Buy and 17 Hold ratings over the past three months. The average price target sits at $205.53, against a current price of around $158.

Lululemon reports after the close on Tuesday, March 17.

The post Lululemon (LULU) Stock: Buy the Dip or Value Trap Before Tuesday’s Earnings? appeared first on CoinCentral.

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0003534
$0.0003534$0.0003534
+0.54%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Swiss Franc Intervention: Critical Analysis of SNB’s 2025 Policy and Safe-Haven Resilience

Swiss Franc Intervention: Critical Analysis of SNB’s 2025 Policy and Safe-Haven Resilience

BitcoinWorld Swiss Franc Intervention: Critical Analysis of SNB’s 2025 Policy and Safe-Haven Resilience ZURICH, March 2025 – The Swiss National Bank faces mounting
Share
bitcoinworld2026/03/16 23:10
Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26